TR200100974T2 - Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi - Google Patents

Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi

Info

Publication number
TR200100974T2
TR200100974T2 TR2001/00974T TR200100974T TR200100974T2 TR 200100974 T2 TR200100974 T2 TR 200100974T2 TR 2001/00974 T TR2001/00974 T TR 2001/00974T TR 200100974 T TR200100974 T TR 200100974T TR 200100974 T2 TR200100974 T2 TR 200100974T2
Authority
TR
Turkey
Prior art keywords
shock
respiratory distress
blocking
systematic
lymphotoxin beta
Prior art date
Application number
TR2001/00974T
Other languages
English (en)
Inventor
Browning Jeff
Pugielli Maryann
Ahmed Rafi
Original Assignee
Biogen, Inc.
Emory Universty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc., Emory Universty filed Critical Biogen, Inc.
Publication of TR200100974T2 publication Critical patent/TR200100974T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bu bulus, bir kisiye, etkili bir miktarda bir LT-B bloke edici madde ve farmasötik açidan kabul edilebilir bir tasiyici tatbik etmek suretiyle, bu kiside antivirütik bir tepki meydana getirmek için yöntemler saglar. Bu bulus özellikle, virüslerin neden oldugu sistemik sok ve solunum zorlugunun tedavi edilmesi için yöntemler saglar.
TR2001/00974T 1998-10-09 1999-10-08 Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi TR200100974T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10366298P 1998-10-09 1998-10-09

Publications (1)

Publication Number Publication Date
TR200100974T2 true TR200100974T2 (tr) 2001-11-21

Family

ID=22296372

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00974T TR200100974T2 (tr) 1998-10-09 1999-10-08 Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi

Country Status (27)

Country Link
US (3) US20020001585A1 (tr)
EP (1) EP1119370B1 (tr)
JP (2) JP4713738B2 (tr)
KR (1) KR100888832B1 (tr)
CN (1) CN1200733C (tr)
AT (1) ATE329618T1 (tr)
AU (1) AU777492C (tr)
BR (1) BR9915025A (tr)
CA (1) CA2344049C (tr)
CY (1) CY1105059T1 (tr)
CZ (1) CZ20011272A3 (tr)
DE (1) DE69931944T2 (tr)
DK (1) DK1119370T3 (tr)
EA (1) EA006703B1 (tr)
EE (1) EE04661B1 (tr)
ES (1) ES2267294T3 (tr)
HU (1) HUP0103773A3 (tr)
IL (2) IL142284A0 (tr)
IS (1) IS2514B (tr)
NO (1) NO326905B1 (tr)
NZ (1) NZ510560A (tr)
PL (1) PL195264B1 (tr)
PT (1) PT1119370E (tr)
SG (1) SG121778A1 (tr)
SK (1) SK4662001A3 (tr)
TR (1) TR200100974T2 (tr)
WO (1) WO2000021558A1 (tr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
TR200100974T2 (tr) * 1998-10-09 2001-11-21 Biogen, Inc. Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
ATE365214T1 (de) * 2000-04-12 2007-07-15 Jolla Inst Allergy Immunolog Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
BRPI0509201A (pt) * 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
NZ576424A (en) 2006-10-20 2012-09-28 Biogen Idec Inc Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP3750554A3 (en) * 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
CN106591446A (zh) * 2016-12-07 2017-04-26 中国人民解放军军事医学科学院微生物流行病研究所 细胞通路调控分子在作为药物靶点及诊断ebov感染中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5670149A (en) * 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
AU692146B2 (en) 1990-06-27 1998-06-04 Biogen Idec Ma Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
DK0536299T3 (da) 1990-06-27 2001-07-09 Univ California Overfladekompleksbundet lymfotolksin
US7030080B2 (en) 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CZ298711B6 (cs) 1995-01-26 2008-01-02 Biogen Idec Ma Inc. Farmaceutické prostredky aktivující LT-beta receptor pro lécení nebo omezení pokracování, závažnosti nebo úcinku neoplazie, zpusob selekce LT-beta receptor aktivujícího cinidla a protilátky proti LT-beta receptoru
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
BR9712670A (pt) * 1996-10-25 1999-10-19 Biogen Inc Receptores para linfotoxina-beta, anticorpos anti-receptor para linfotoxina, e anticorpos antiligante de linfotoxina como agentes terapêuticos para o tratamento de doencas imunológicas
US7255854B1 (en) 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
TR200100974T2 (tr) * 1998-10-09 2001-11-21 Biogen, Inc. Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体

Also Published As

Publication number Publication date
JP4713738B2 (ja) 2011-06-29
CY1105059T1 (el) 2010-03-03
PL195264B1 (pl) 2007-08-31
NO20011757D0 (no) 2001-04-06
KR100888832B1 (ko) 2009-03-17
CN1323223A (zh) 2001-11-21
DE69931944T2 (de) 2007-02-08
CA2344049A1 (en) 2000-04-20
AU6296499A (en) 2000-05-01
CN1200733C (zh) 2005-05-11
US20040198635A1 (en) 2004-10-07
ATE329618T1 (de) 2006-07-15
US20020001585A1 (en) 2002-01-03
NO20011757L (no) 2001-06-08
ES2267294T3 (es) 2007-03-01
PT1119370E (pt) 2006-09-29
DE69931944D1 (de) 2006-07-27
NO326905B1 (no) 2009-03-16
WO2000021558A1 (en) 2000-04-20
IS5882A (is) 2001-03-09
SK4662001A3 (en) 2001-11-06
DK1119370T3 (da) 2006-10-02
EE200100211A (et) 2002-08-15
WO2000021558A9 (en) 2001-05-25
HUP0103773A3 (en) 2003-10-28
CZ20011272A3 (cs) 2001-09-12
SG121778A1 (en) 2006-05-26
NZ510560A (en) 2003-09-26
CA2344049C (en) 2009-12-15
HUP0103773A2 (hu) 2002-01-28
US20090087403A1 (en) 2009-04-02
EA006703B1 (ru) 2006-02-24
US7452530B2 (en) 2008-11-18
AU777492B2 (en) 2004-10-21
IL142284A0 (en) 2002-03-10
EP1119370A1 (en) 2001-08-01
IS2514B (is) 2009-06-15
PL347177A1 (en) 2002-03-25
EE04661B1 (et) 2006-08-15
KR20010080073A (ko) 2001-08-22
EA200100430A1 (ru) 2001-10-22
EP1119370B1 (en) 2006-06-14
BR9915025A (pt) 2001-08-14
JP2010155852A (ja) 2010-07-15
JP2002527403A (ja) 2002-08-27
AU777492C (en) 2005-05-26
IL142284A (en) 2009-11-18

Similar Documents

Publication Publication Date Title
TR199903053T2 (tr) Benzimidazol türevleri.
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
TR199801315T2 (tr) X sendromunun tedavisi için bir ppar-alpha ve ppar-gamma antagonistinin kullanilmasi.
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
TR200002355T2 (tr) 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
BR9707233A (pt) Fenantridinas
TR199801930T2 (tr) 6-Fenilpiridil-2-amin türevleri.
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
DK0889886T5 (da) Hidtil ukendte, i 6-stilling substituerede phenanthridiner
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
EA200000797A1 (ru) Микрогранулы омепразола, защищенные от желудочного сока, способ их получения и фармацевтические препараты
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
CY1105059T1 (el) Αντιστροφη του συστηματικου σοκ επαγομενου απο ιο και της αναπνευστικης καταπονησης με το μπλοκαρισμα της οδου της λεμφοτοξινης-βητα
TR200200359T2 (tr) Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
DE69836678D1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
TR199900951T2 (tr) Gögüs kanserinin engellenmesi için yöntemler.
AR002987A1 (es) Composicion farmaceutica para el tratamiento de infecciones virales ocanceres o tumores, composicion de dosis unitaria que la comprende y uso para dicho tratamiento
TR199801289T2 (tr) Terapötik bilesikler.
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
DE60135743D1 (de) Liposomale einkapselung von alphastrahlern, und deren verwendung
ATE468130T1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie